# A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis

> **NCT00721123** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 538 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT00721123
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 538 (ACTUAL)
- **Last updated:** 2013-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721123, "A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00721123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*